Form 4: Moderna Chief Legal Officer Shannon Klinger Executes Stock Transactions

Moderna's Chief Legal Officer, Shannon Klinger, engaged in stock transactions involving the vesting of restricted stock units and subsequent sales to cover tax obligations.

Summary

• Shannon Klinger, Chief Legal Officer at Moderna, executed multiple transactions involving the company's stock.
• On November 27, 2024, Klinger acquired 329 shares of common stock and 2,652 shares of common stock through the vesting of restricted stock units (RSUs).
• These RSUs convert to common stock on a one-for-one basis.
• On November 29, 2024, Klinger sold 1,418 shares of common stock at a price of $42.7891 per share.
• The sale of shares was to cover tax withholding obligations related to the vesting of the RSUs.
• Following these transactions, Klinger directly owns 19,717 shares of common stock.

Sentiment

Score: 5

Explanation: The document reflects routine transactions related to executive compensation and does not indicate any positive or negative sentiment. It is a standard regulatory filing.

Industry Context

This is a routine filing related to executive compensation and is common for publicly traded companies. It reflects the vesting of equity awards and subsequent sales to cover tax liabilities.

Comparison to Industry Standards

• The vesting of restricted stock units and subsequent sales to cover taxes are standard practices in executive compensation across the biotechnology and pharmaceutical industries.
• Many companies, such as BioNTech and Pfizer, use similar equity compensation structures for their executives.
• The 'sell to cover' mechanism is a common method to manage tax obligations associated with equity awards.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are part of routine executive compensation practices.
• The sale of shares to cover taxes does not indicate any change in the company's fundamentals.

Key Dates

Keywords

Moderna, MRNA, stock transactions, restricted stock units, RSU, insider trading, Form 4, Shannon Klinger, Chief Legal Officer, equity compensation